Transformation of the Russian pharmaceutical market under the influence of macroeconomic factors

the article examines the processes of transformation of the Russian pharmaceutical market under the influence of macroeconomic factors during the period 2020–2025. The relevance of the study is determined by the changes in the structure of supply and demand in the pharmaceutical market under the impact of the COVID-19 pandemic, exchange rate fluctuations, inflation, as well as sanction pressure. Purpose: to characterize the current state of the Russian pharmaceutical market, identify key trends in its development, and determine the prospects for import substitution in the segment of innovative drugs. Methods: the study is based on the analysis of statistical data, scientific literature, and regulatory documents, as well as the application of SWOT analysis to assess the consequences of sanction pressure on domestic manufacturers. The article presents the results of analyzing the dynamics of the pharmaceutical market in value and physical terms, considers changes in the structure of the retail and public segments, import substitution trends, and the reconfiguration of supply chains. Special attention is given to the diversification of external supplies, the role of India and China as key partners, and state policy in supporting localization of production and R&D. Results: the study highlights the accelerated growth of generics and biosimilars, the increasing trust of doctors and patients in domestic drugs, the diversification of logistics routes, and the formation of new partnerships with friendly countries. Conclusion: the transformation of the Russian pharmaceutical market is evolutionary in nature. In the coming years, generics and biosimilars will play the leading role, while the formation of the innovative drug segment will develop gradually, supported by the state, the deepening of production localization, and the expansion of international partnerships.

pharmaceutical market, macroeconomic factors, import substitution of medicines, generics and biosimilars, pharmaceutical logistics, state support of the pharmaceutical market